Antiviral treatment in congenital HCMV infection: The six-year experience of a single neonatal center in Poland

Antiviral treatment is recommended for symptomatic newborns with congenital cytomegalovirus infection (cCMV). To compare 2 treatment methods in neonates with cCMV - ganciclovir-based therapy (intravenous ganciclovir (GCV) or sequential GCV + valganciclovir (VGCV) therapy) with oral VGCV-based therap...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Advances in clinical and experimental medicine : official organ Wroclaw Medical University 2020-10, Vol.29 (10), p.1161-1167
Hauptverfasser: Jedlińska-Pijanowska, Dominika, Czech-Kowalska, Justyna, Kłodzińska, Magdalena, Pietrzyk, Aleksandra, Michalska, Eliza, Gradowska, Kinga, Dobrzańska, Anna, Kasztelewicz, Beata, Gruszfeld, Dariusz
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1167
container_issue 10
container_start_page 1161
container_title Advances in clinical and experimental medicine : official organ Wroclaw Medical University
container_volume 29
creator Jedlińska-Pijanowska, Dominika
Czech-Kowalska, Justyna
Kłodzińska, Magdalena
Pietrzyk, Aleksandra
Michalska, Eliza
Gradowska, Kinga
Dobrzańska, Anna
Kasztelewicz, Beata
Gruszfeld, Dariusz
description Antiviral treatment is recommended for symptomatic newborns with congenital cytomegalovirus infection (cCMV). To compare 2 treatment methods in neonates with cCMV - ganciclovir-based therapy (intravenous ganciclovir (GCV) or sequential GCV + valganciclovir (VGCV) therapy) with oral VGCV-based therapy - in Polish neonates. A total of 98 symptomatic infants with cCMV (positive HCMV DNA in urine ≤21st day of life) hospitalized in the neonatal intensive care unit (NICU) between 2012 and 2017 were enrolled. Clinical characteristics, the viral load in blood and urine, hematological and biochemical tests, neuroimaging results, and the length of hospitalization were compared between the study groups at baseline and at the 2nd hospitalization. In 2012, GCV was used in 57% of the cases, sequential therapy in 33% and VGCV in 10%. In 2017, VGCV monotherapy was used in 83% of the infants treated. Valganciclovir treatment allowed the length of hospitalization to be shortened over 2.5 times during the six-year observation period. Infants treated intravenously had lower birth weights and head circumferences, and more frequently presented splenomegaly, petechiae, thrombocytopenia, and hepatitis. The baseline viral load in the blood and urine were similar in both groups, but at follow-up visits 4-6 weeks later, a viral load about 70 times lower was observed in the blood of the VGCV-based group (1029 viral copies/mL compared to 72,188 viral copies/mL in the GCV-based group; p = 0.04). The prevalence of neutropenia was similar in both groups at the follow-up visits. Valganciclovir became the first line of antiviral therapy in cCMV in the study population. Compared to GCV-based therapy, VGCV monotherapy allowed shorter hospital stays and reduced the viral load in blood due to continuing treatment at home. Valganciclovir monotherapy did not provoke more side effects such as neutropenia. Intravenous GCV is still suitable for patients with severe disseminated disease, born prematurely, with low birth weights, or not tolerating enteral feeding. In those infants, the sequential therapy seems to be optimal.
doi_str_mv 10.17219/acem/125427
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2451381036</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2451381036</sourcerecordid><originalsourceid>FETCH-LOGICAL-c329t-25d7055811b53c9918f36d806665d355d8ab3fb8dff729bf1814cd8737b28f2f3</originalsourceid><addsrcrecordid>eNo9kDFPwzAQRj2AKCrdmJFHBkJjO05stqoCigSCobBGjnMuRold7BS1_x6XArecdPfu0-khdE7ya1JRIqdKQz8llBe0OkKnREiZcVqVIzSJ8SNPVUgq8-IEjRjLOaMVP0V-5gb7ZYPq8BBADT24AVuHtXcrcHZI88X86S2NDOjBeneDl--Ao91mO1ABw3YNwYLTgL3BKi3cqgPswDu1P9YpD8I-8cV3yrVn6NioLsLkt4_R693tcr7IHp_vH-azx0wzKoeM8rbKOReENJxpKYkwrGxFXpYlbxnnrVANM41ojamobAwRpNCtqFjVUGGoYWN0echdB_-5gTjUvY0auvQD-E2sacEJEyRnZUKvDqgOPsYApl4H26uwq0le_5it92brg9mEX_wmb5oe2n_4zyn7BsDCdjM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2451381036</pqid></control><display><type>article</type><title>Antiviral treatment in congenital HCMV infection: The six-year experience of a single neonatal center in Poland</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Jedlińska-Pijanowska, Dominika ; Czech-Kowalska, Justyna ; Kłodzińska, Magdalena ; Pietrzyk, Aleksandra ; Michalska, Eliza ; Gradowska, Kinga ; Dobrzańska, Anna ; Kasztelewicz, Beata ; Gruszfeld, Dariusz</creator><creatorcontrib>Jedlińska-Pijanowska, Dominika ; Czech-Kowalska, Justyna ; Kłodzińska, Magdalena ; Pietrzyk, Aleksandra ; Michalska, Eliza ; Gradowska, Kinga ; Dobrzańska, Anna ; Kasztelewicz, Beata ; Gruszfeld, Dariusz</creatorcontrib><description>Antiviral treatment is recommended for symptomatic newborns with congenital cytomegalovirus infection (cCMV). To compare 2 treatment methods in neonates with cCMV - ganciclovir-based therapy (intravenous ganciclovir (GCV) or sequential GCV + valganciclovir (VGCV) therapy) with oral VGCV-based therapy - in Polish neonates. A total of 98 symptomatic infants with cCMV (positive HCMV DNA in urine ≤21st day of life) hospitalized in the neonatal intensive care unit (NICU) between 2012 and 2017 were enrolled. Clinical characteristics, the viral load in blood and urine, hematological and biochemical tests, neuroimaging results, and the length of hospitalization were compared between the study groups at baseline and at the 2nd hospitalization. In 2012, GCV was used in 57% of the cases, sequential therapy in 33% and VGCV in 10%. In 2017, VGCV monotherapy was used in 83% of the infants treated. Valganciclovir treatment allowed the length of hospitalization to be shortened over 2.5 times during the six-year observation period. Infants treated intravenously had lower birth weights and head circumferences, and more frequently presented splenomegaly, petechiae, thrombocytopenia, and hepatitis. The baseline viral load in the blood and urine were similar in both groups, but at follow-up visits 4-6 weeks later, a viral load about 70 times lower was observed in the blood of the VGCV-based group (1029 viral copies/mL compared to 72,188 viral copies/mL in the GCV-based group; p = 0.04). The prevalence of neutropenia was similar in both groups at the follow-up visits. Valganciclovir became the first line of antiviral therapy in cCMV in the study population. Compared to GCV-based therapy, VGCV monotherapy allowed shorter hospital stays and reduced the viral load in blood due to continuing treatment at home. Valganciclovir monotherapy did not provoke more side effects such as neutropenia. Intravenous GCV is still suitable for patients with severe disseminated disease, born prematurely, with low birth weights, or not tolerating enteral feeding. In those infants, the sequential therapy seems to be optimal.</description><identifier>ISSN: 1899-5276</identifier><identifier>DOI: 10.17219/acem/125427</identifier><identifier>PMID: 33053275</identifier><language>eng</language><publisher>Poland</publisher><subject>Antiviral Agents - therapeutic use ; Cytomegalovirus Infections - drug therapy ; Ganciclovir - therapeutic use ; Humans ; Infant ; Infant, Newborn ; Poland ; Valganciclovir</subject><ispartof>Advances in clinical and experimental medicine : official organ Wroclaw Medical University, 2020-10, Vol.29 (10), p.1161-1167</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c329t-25d7055811b53c9918f36d806665d355d8ab3fb8dff729bf1814cd8737b28f2f3</citedby><orcidid>0000-0002-0913-8116 ; 0000-0002-2414-4928 ; 0000-0003-0519-2278 ; 0000-0003-2927-2344 ; 0000-0001-7381-3254 ; 0000-0002-0173-1150 ; 0000-0003-1504-5589 ; 0000-0001-7563-3951 ; 0000-0003-1535-1332</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,864,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33053275$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jedlińska-Pijanowska, Dominika</creatorcontrib><creatorcontrib>Czech-Kowalska, Justyna</creatorcontrib><creatorcontrib>Kłodzińska, Magdalena</creatorcontrib><creatorcontrib>Pietrzyk, Aleksandra</creatorcontrib><creatorcontrib>Michalska, Eliza</creatorcontrib><creatorcontrib>Gradowska, Kinga</creatorcontrib><creatorcontrib>Dobrzańska, Anna</creatorcontrib><creatorcontrib>Kasztelewicz, Beata</creatorcontrib><creatorcontrib>Gruszfeld, Dariusz</creatorcontrib><title>Antiviral treatment in congenital HCMV infection: The six-year experience of a single neonatal center in Poland</title><title>Advances in clinical and experimental medicine : official organ Wroclaw Medical University</title><addtitle>Adv Clin Exp Med</addtitle><description>Antiviral treatment is recommended for symptomatic newborns with congenital cytomegalovirus infection (cCMV). To compare 2 treatment methods in neonates with cCMV - ganciclovir-based therapy (intravenous ganciclovir (GCV) or sequential GCV + valganciclovir (VGCV) therapy) with oral VGCV-based therapy - in Polish neonates. A total of 98 symptomatic infants with cCMV (positive HCMV DNA in urine ≤21st day of life) hospitalized in the neonatal intensive care unit (NICU) between 2012 and 2017 were enrolled. Clinical characteristics, the viral load in blood and urine, hematological and biochemical tests, neuroimaging results, and the length of hospitalization were compared between the study groups at baseline and at the 2nd hospitalization. In 2012, GCV was used in 57% of the cases, sequential therapy in 33% and VGCV in 10%. In 2017, VGCV monotherapy was used in 83% of the infants treated. Valganciclovir treatment allowed the length of hospitalization to be shortened over 2.5 times during the six-year observation period. Infants treated intravenously had lower birth weights and head circumferences, and more frequently presented splenomegaly, petechiae, thrombocytopenia, and hepatitis. The baseline viral load in the blood and urine were similar in both groups, but at follow-up visits 4-6 weeks later, a viral load about 70 times lower was observed in the blood of the VGCV-based group (1029 viral copies/mL compared to 72,188 viral copies/mL in the GCV-based group; p = 0.04). The prevalence of neutropenia was similar in both groups at the follow-up visits. Valganciclovir became the first line of antiviral therapy in cCMV in the study population. Compared to GCV-based therapy, VGCV monotherapy allowed shorter hospital stays and reduced the viral load in blood due to continuing treatment at home. Valganciclovir monotherapy did not provoke more side effects such as neutropenia. Intravenous GCV is still suitable for patients with severe disseminated disease, born prematurely, with low birth weights, or not tolerating enteral feeding. In those infants, the sequential therapy seems to be optimal.</description><subject>Antiviral Agents - therapeutic use</subject><subject>Cytomegalovirus Infections - drug therapy</subject><subject>Ganciclovir - therapeutic use</subject><subject>Humans</subject><subject>Infant</subject><subject>Infant, Newborn</subject><subject>Poland</subject><subject>Valganciclovir</subject><issn>1899-5276</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kDFPwzAQRj2AKCrdmJFHBkJjO05stqoCigSCobBGjnMuRold7BS1_x6XArecdPfu0-khdE7ya1JRIqdKQz8llBe0OkKnREiZcVqVIzSJ8SNPVUgq8-IEjRjLOaMVP0V-5gb7ZYPq8BBADT24AVuHtXcrcHZI88X86S2NDOjBeneDl--Ao91mO1ABw3YNwYLTgL3BKi3cqgPswDu1P9YpD8I-8cV3yrVn6NioLsLkt4_R693tcr7IHp_vH-azx0wzKoeM8rbKOReENJxpKYkwrGxFXpYlbxnnrVANM41ojamobAwRpNCtqFjVUGGoYWN0echdB_-5gTjUvY0auvQD-E2sacEJEyRnZUKvDqgOPsYApl4H26uwq0le_5it92brg9mEX_wmb5oe2n_4zyn7BsDCdjM</recordid><startdate>20201001</startdate><enddate>20201001</enddate><creator>Jedlińska-Pijanowska, Dominika</creator><creator>Czech-Kowalska, Justyna</creator><creator>Kłodzińska, Magdalena</creator><creator>Pietrzyk, Aleksandra</creator><creator>Michalska, Eliza</creator><creator>Gradowska, Kinga</creator><creator>Dobrzańska, Anna</creator><creator>Kasztelewicz, Beata</creator><creator>Gruszfeld, Dariusz</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0913-8116</orcidid><orcidid>https://orcid.org/0000-0002-2414-4928</orcidid><orcidid>https://orcid.org/0000-0003-0519-2278</orcidid><orcidid>https://orcid.org/0000-0003-2927-2344</orcidid><orcidid>https://orcid.org/0000-0001-7381-3254</orcidid><orcidid>https://orcid.org/0000-0002-0173-1150</orcidid><orcidid>https://orcid.org/0000-0003-1504-5589</orcidid><orcidid>https://orcid.org/0000-0001-7563-3951</orcidid><orcidid>https://orcid.org/0000-0003-1535-1332</orcidid></search><sort><creationdate>20201001</creationdate><title>Antiviral treatment in congenital HCMV infection: The six-year experience of a single neonatal center in Poland</title><author>Jedlińska-Pijanowska, Dominika ; Czech-Kowalska, Justyna ; Kłodzińska, Magdalena ; Pietrzyk, Aleksandra ; Michalska, Eliza ; Gradowska, Kinga ; Dobrzańska, Anna ; Kasztelewicz, Beata ; Gruszfeld, Dariusz</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c329t-25d7055811b53c9918f36d806665d355d8ab3fb8dff729bf1814cd8737b28f2f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Antiviral Agents - therapeutic use</topic><topic>Cytomegalovirus Infections - drug therapy</topic><topic>Ganciclovir - therapeutic use</topic><topic>Humans</topic><topic>Infant</topic><topic>Infant, Newborn</topic><topic>Poland</topic><topic>Valganciclovir</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jedlińska-Pijanowska, Dominika</creatorcontrib><creatorcontrib>Czech-Kowalska, Justyna</creatorcontrib><creatorcontrib>Kłodzińska, Magdalena</creatorcontrib><creatorcontrib>Pietrzyk, Aleksandra</creatorcontrib><creatorcontrib>Michalska, Eliza</creatorcontrib><creatorcontrib>Gradowska, Kinga</creatorcontrib><creatorcontrib>Dobrzańska, Anna</creatorcontrib><creatorcontrib>Kasztelewicz, Beata</creatorcontrib><creatorcontrib>Gruszfeld, Dariusz</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Advances in clinical and experimental medicine : official organ Wroclaw Medical University</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jedlińska-Pijanowska, Dominika</au><au>Czech-Kowalska, Justyna</au><au>Kłodzińska, Magdalena</au><au>Pietrzyk, Aleksandra</au><au>Michalska, Eliza</au><au>Gradowska, Kinga</au><au>Dobrzańska, Anna</au><au>Kasztelewicz, Beata</au><au>Gruszfeld, Dariusz</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antiviral treatment in congenital HCMV infection: The six-year experience of a single neonatal center in Poland</atitle><jtitle>Advances in clinical and experimental medicine : official organ Wroclaw Medical University</jtitle><addtitle>Adv Clin Exp Med</addtitle><date>2020-10-01</date><risdate>2020</risdate><volume>29</volume><issue>10</issue><spage>1161</spage><epage>1167</epage><pages>1161-1167</pages><issn>1899-5276</issn><abstract>Antiviral treatment is recommended for symptomatic newborns with congenital cytomegalovirus infection (cCMV). To compare 2 treatment methods in neonates with cCMV - ganciclovir-based therapy (intravenous ganciclovir (GCV) or sequential GCV + valganciclovir (VGCV) therapy) with oral VGCV-based therapy - in Polish neonates. A total of 98 symptomatic infants with cCMV (positive HCMV DNA in urine ≤21st day of life) hospitalized in the neonatal intensive care unit (NICU) between 2012 and 2017 were enrolled. Clinical characteristics, the viral load in blood and urine, hematological and biochemical tests, neuroimaging results, and the length of hospitalization were compared between the study groups at baseline and at the 2nd hospitalization. In 2012, GCV was used in 57% of the cases, sequential therapy in 33% and VGCV in 10%. In 2017, VGCV monotherapy was used in 83% of the infants treated. Valganciclovir treatment allowed the length of hospitalization to be shortened over 2.5 times during the six-year observation period. Infants treated intravenously had lower birth weights and head circumferences, and more frequently presented splenomegaly, petechiae, thrombocytopenia, and hepatitis. The baseline viral load in the blood and urine were similar in both groups, but at follow-up visits 4-6 weeks later, a viral load about 70 times lower was observed in the blood of the VGCV-based group (1029 viral copies/mL compared to 72,188 viral copies/mL in the GCV-based group; p = 0.04). The prevalence of neutropenia was similar in both groups at the follow-up visits. Valganciclovir became the first line of antiviral therapy in cCMV in the study population. Compared to GCV-based therapy, VGCV monotherapy allowed shorter hospital stays and reduced the viral load in blood due to continuing treatment at home. Valganciclovir monotherapy did not provoke more side effects such as neutropenia. Intravenous GCV is still suitable for patients with severe disseminated disease, born prematurely, with low birth weights, or not tolerating enteral feeding. In those infants, the sequential therapy seems to be optimal.</abstract><cop>Poland</cop><pmid>33053275</pmid><doi>10.17219/acem/125427</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-0913-8116</orcidid><orcidid>https://orcid.org/0000-0002-2414-4928</orcidid><orcidid>https://orcid.org/0000-0003-0519-2278</orcidid><orcidid>https://orcid.org/0000-0003-2927-2344</orcidid><orcidid>https://orcid.org/0000-0001-7381-3254</orcidid><orcidid>https://orcid.org/0000-0002-0173-1150</orcidid><orcidid>https://orcid.org/0000-0003-1504-5589</orcidid><orcidid>https://orcid.org/0000-0001-7563-3951</orcidid><orcidid>https://orcid.org/0000-0003-1535-1332</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1899-5276
ispartof Advances in clinical and experimental medicine : official organ Wroclaw Medical University, 2020-10, Vol.29 (10), p.1161-1167
issn 1899-5276
language eng
recordid cdi_proquest_miscellaneous_2451381036
source MEDLINE; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals
subjects Antiviral Agents - therapeutic use
Cytomegalovirus Infections - drug therapy
Ganciclovir - therapeutic use
Humans
Infant
Infant, Newborn
Poland
Valganciclovir
title Antiviral treatment in congenital HCMV infection: The six-year experience of a single neonatal center in Poland
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T02%3A23%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antiviral%20treatment%20in%20congenital%20HCMV%20infection:%20The%20six-year%20experience%20of%20a%20single%20neonatal%20center%20in%20Poland&rft.jtitle=Advances%20in%20clinical%20and%20experimental%20medicine%20:%20official%20organ%20Wroclaw%20Medical%20University&rft.au=Jedli%C5%84ska-Pijanowska,%20Dominika&rft.date=2020-10-01&rft.volume=29&rft.issue=10&rft.spage=1161&rft.epage=1167&rft.pages=1161-1167&rft.issn=1899-5276&rft_id=info:doi/10.17219/acem/125427&rft_dat=%3Cproquest_cross%3E2451381036%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2451381036&rft_id=info:pmid/33053275&rfr_iscdi=true